About Dr. Daugherty, M.D., M.S.I.A.
Dr. Joseph Daugherty
2002 – Present: Phenolics LLC. Managing Partner and founder, and, President TerraPharm Inc., Managing Partner PharmaPrint, LLC, wholly-owned subsidiaries
2005 – Present: CEO & CMO, Eleos Inc. Oversees administrative, commercial and business development, manufacturing, finance, clinical monitoring and active in all aspects of clinical development of this hematology/oncology product development company.
1990 – Present: Management Consultant, Biomedical Technology Consulting
Private practice specializing in strategic planning, organizational and business development, technology licensing, mergers and acquisitions.
UNeTech – Advisory Committee Member
Past Projects: Trimed Research (Chariman), ActivBiotics, Alpine Surgical, American Securities, Amerifit Nutrition, BioBalance, Cardiox (CEO), Transgenomic, Nobex Corporation, Nutrition 21, Ximerex, Hesed Biomed, University of Nebraska School of Medicine, ConLinco, Autogenics, GalaGen, Orphan Medical, Tacora Corporation (Chairman), Beacon Laboratories, Oakmont Pharmaceuticals, Larex, Healthcare Software Solutions, Oxis International, Spectra Biomedical, Phyton, Inc., MacroChem, DuPont / ConAgra Ventures (DCV), and Principal of Grayson & Associates, a business development and investment banking enterprise.
1988 – 1990: President, Biotechnology Division, Monfort, Inc. Division of ConAgra
Established a venture for processing of animal-based pharmaceutical by-products.
1987: Vice-President Planning and Development, Centennial Corporation
Initiated new business activities for processing of pharmaceutical by-products from food processing, and the start-up of sterile medical device production.
1986: President, Culture Technologies, Inc.
A start-up devoted to the production of sterile medical devices for tissue culture media and pharmaceutical industry manufacturing components.
1979 – 1984: Management Consultant in several biomedical technology start-ups
Clients included Bactex, Inc., Provac, Inc., Actronics, Inc., and Suprex, Inc. A variety of functions were performed including board membership, market research, strategic planning, soliciting venture capital, etc.
1979 M.S.I.A., Carnegie-Mellon University, Graduate School of Industrial Administration
1975 M.D., University of Nebraska School of Medicine
1972 A.B., Washington University
CardioBar® is not intended to treat or prevent illness, nor is it presented as a replacement for medications. The Portfolio Diet has been clinically reviewed and suggested as an alternative option for people that have borderline risk factor cholesterol levels. Because of this clinical review, CardioBar® has been designed, formulated and created to contain all the natural ingredients contained in The Portfolio Diet. CardioBar® is a unique functional food. The Portfolio Diet contained in CardioBar® has been recommended as a safe alternative for anyone desiring to lower their cholesterol. Persons engaging in a self-care program should always seek the guidance and monitoring by their primary health care provider.